Ofer Gonen is the Chief Executive Officer at Clal Biotechnology Industries Ltd. (TASE:CBI) since 2017, managing CBI’s life science investments and business development in both the United States and Israel. Mr. Gonen serves as a Board Member of several portfolio companies, including Gamida Cell Ltd. (Nasdaq: GMDA) and MediWound Ltd. (Nasdaq: MDWD). Prior to joining CBI, Mr. Gonen was the General Manager of Biomedical Investments Ltd., a partner at Arte Venture Group, as well as a technology consultant to various Israeli venture capital funds. Mr. Gonen gained extensive experience in R&D and management of defense-oriented projects within the prestigious “Talpiot” program of the Israeli Defence Forces. Mr. Gonen holds a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, Israel.